Trials / Not Yet Recruiting
Not Yet RecruitingNCT06468670
Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is aimed to evaluate the efficacy and safety of short-course radiotherapy combined with sintilimab in neoadjuvant treatment of stage III, locally advanced esophageal squamous cell carcinoma.
Detailed description
This study was designed as a single arm, phase II trial. Subjects will receive short-course radiotherapy combined with sintilimab as neoadjuvant therapy of stage III, locally advanced esophageal squamous cell carcinoma. The primary endpoint is pathologic complete response(pCR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sintilimab，programmed death 1 monoclonal antibody | short-course radiotherapy +sintilimab (200mg, iv, D1, Q3W) |
Timeline
- Start date
- 2024-06-17
- Primary completion
- 2025-06-01
- Completion
- 2027-06-01
- First posted
- 2024-06-21
- Last updated
- 2024-06-21
Source: ClinicalTrials.gov record NCT06468670. Inclusion in this directory is not an endorsement.